Tibor Keler - Celldex Therapeutics Insider

Celldex Therapeutics Inc -- USA Stock  

USD 2.93  0.1  3.3%

Founder, Chief Scientific Officer and Executive VP

Dr. Tibor Keler, Ph.D., serves as Executive Vice President and Chief Scientific Officer of Celldex Therapeutics Inc. since July 30, 2014. Since, May 2003, Dr. Keler has held a number of positions with Celldex, including a founder, Senior Vice President and Chief Scientific Officer of Celldex, from March 2008 to July 2014, and Vice President, Research and Discovery and Chief Scientific Officer, from May 2003 to March 2008. In addition, he was Senior Director of Preclinical Development and Principal Scientist at Medarex from September 1993 to March 2004. While at Medarex, he was responsible for the development of Celldex technology and products, as well as for the preclinical development and testing of numerous Medarex products now in clinical trials
Age: 57  Founder Since 2014  Ph.D    
908-200-7500  http://www.celldextherapeutics.com
Keler received his Ph.D. in Microbiology from the University of Pennsylvania.

Management Efficiency

The company has return on total asset (ROA) of (24.34) % which means that it has lost $24.34 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (53.51) % meaning that it created substantial loss on money invested by shareholders.

Entity Summary

Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care. Celldex Therapeutics Inc (CLDX) is traded on NASDAQ in USA. It is located in NEW JERSEY, U.S.A and employs 196 people. Celldex Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Equity Valuation Now
   

Equity Valuation

Check real value of public entities based on technical and fundamental data
Hide  View All  NextLaunch Equity Valuation
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Celldex Therapeutics Inc to your portfolio

Top Management

Celldex Therapeutics Inc Leadership Team
Theresa LaVallee, President, Ph.D
Keith Brownlie, Director
Ronald Pepin, SVP, Ph.D
Harry Penner, Director
Sam Martin, President, MBA
Karen Shoos, Director
Gerald McMahon, Director, Ph.D
Sarah Cavanaugh, President
Richard Broek, Director
Anthony Marucci, CEO, MBA
James Marino, Director, MBA
George Elston, Director
Thomas Davis, President
Avery Catlin, CFO, MBA
Richard Wright, President, MBA
Elizabeth Crowley, President
Larry Ellberger, Chairman
Herbert Conrad, Director
Margo HeathChiozzi, President
Tibor Keler, Founder, Ph.D

Stock Performance

Celldex Therapeutics Performance Indicators